ISSN:
1573-0646
Keywords:
Doxil®
;
mesothelioma
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Abstract Twenty-four patients with pleural mesotheliomareceived 50 mg/m2 of Doxil® every four weeks.At follow-up, the disease had stabilized in 43% percent ofpatients and had progressed in 57%. No objective responses wereobserved. Estimated median survival of all patients was 37 weeks.Major toxicities were erythrodysesthesia of hands and feet andmyelosuppression. No cardiac toxicity was observed. We concludedthat Doxil® at this dosage and schedule is inactiveagainst pleural mesothelioma.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1006421706540
Permalink